October 27, 2020 -- Genome & Company has initiated clinical testing of GEN-001, an anti-cancer microbiome therapeutic, six months after its investigational new drug approval.
The phase Ib clinical trial will evaluate the oral microbiology therapy candidate in combination with avelumab (Bavencio), an anti-programmed cell death ligand 1 (PD-L1) checkpoint inhibitor in patients with a variety of solid tumors. Bavencio is being jointly developed by Merck and Pfizer.
A total of three trial centers including Oregon Health and Science University Knight Cancer Institute will complete the dose escalation cohort in the first half of 2021.
Under the agreement, Genome & Company will sponsor the study and Merck and Pfizer will supply Bavencio for the phase I/IB clinical trial.
Copyright © 2020 scienceboard.net